关键数据
5.190今开
5.220最高
111.06K成交量
2.05市盈率 TTM
亏损市盈率动
--股息TTM
0.92%换手率
5.170昨收
4.950最低
420.43K成交额
亏损市盈率静
5.62市净率
0.00%股息率 TTM
42.24%ROA
13.74052周最高
2.13量比
-31.40M净利润
12.10M总股本
2.4434每股收益TTM
0.88Beta
-16631.70%ROE
5.06052周最低
5.22%振幅
45.82%毛利率
60.63M总市值
-5.45回报/风险
3.03%风险率
操作建议
LENSAR Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名55/199位。机构持股占比非常高,近一月多位分析师给出公司评级为强力买入。最高目标价8.50。中期看,股价处于平稳状态。近一个月,市场表现非常差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
LENSAR Inc新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
Edwards Lifesciences Corp
EW
33
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
LENSAR Inc简介
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
公司代码LNSR
公司LENSAR Inc
CEOCurtis (Nicholas T)
网址https://www.lensar.com/
公司股东
常见问题
LENSAR Inc(LNSR)的当前股价是多少?
LENSAR Inc(LNSR)的当前股价是 5.07。
LENSAR Inc股票的52周最高点是13.74。
LENSAR Inc股票的52周最低点是5.06。
现在LENSAR Inc(LNSR)的股票是买入、持有还是卖出?
根据分析师评级,LENSAR Inc(LNSR)的总体评级为STRONG BUY,目标价格为8.50。
LENSAR Inc(LNSR)股票的每股收益(EPS TTM)是多少
LENSAR Inc(LNSR)股票的每股收益(EPS TTM)是-2.87。